Risperdal Accords Don't Mean Swift End to Litigation by P.J. D'Annunzio, The Legal Intelligencer After settlement of the third case to head to the courtroom in Philadelphia's Risperdal mass tort, the lead trial attorney for the plaintiffs said it is too soon to expect a global resolution of the litigation. On May 27, the day opening arguments were scheduled in Walker v. Janssen Pharm

Stephen Sheller was honored with a Lifetime Achievement Award Wednesday, May 20 2015 from American Lawyer Media's daily newspaper, The Legal Intelligencer. The award was based on his record of verdicts and settlements, service to clients, dedication to the practice, and support of legal education.     The Legal Intelligencer, May 20, 2015: "Stephen A. Sheller is the founding

American Lawyer Media’s Top Pennsylvania Verdicts and Settlements for 2014 reveals Sheller, P.C. in a familiar spot again in 2014. The firm has been at or near the top of the list for five of the last six years. This year the firm pulled both the #6 and #11 Top Settlements spots based on its legendary strength in whistleblower “qui tam” lawsuits. The #6 ranking: in September 2014, the Shel

April 27, 2010: In the third record whistleblower settlement for Sheller, P.C. in fifteen months, the firm represented a whistleblower who brought forth knowledge of wrongdoing by AstraZeneca. AstraZeneca agreed to a civil settlement of $520 million for charges of off-label marketing of the powerful antipsychotic drug Seroquel. The settlement is the largest pharmaceutical civil settlement and

Pfizer Inc. ignored a 2005 FDA warning letter to stop promoting its antibiotic Zyvox@ as clinically superior to the significantly less expensive, generic vancomycin when its own FDA-approved label indicated otherwise. The drug giant also defrauded federal and state taxpayers by marketing Zyvox@ off-label, according to a qui tam whistleblower complaint filed by Sheller, P.C. attorneys and other doc